cpt code for cell free dna test

cpt code for cell free dna test

Sensitivity was reported as A subset analysis performed by an independent laboratory confirmed these results. Other Aneuploidies Researchers are also investigating if maternal cell-free fetal DNA sequencing has the capability to detect other aneuploidies, such as trisomy 18 and Sehnert and colleagues investigated the ability of MPS of cell-free fetal DNA from maternal blood to detect trisomy Blood samples were collected from female participants at 13 clinics in the United States before they underwent an invasive prenatal procedure.

Fifty-three sequenced samples came from women with an abnormal fetal karyotype. In order to minimize the intra- and inter-run sequencing variation, the researchers developed an algorithm by using normalized chromosome values from the sequencing data on a training set of 71 samples with 26 abnormal karyotypes. The classification process was then evaluated on an independent test set of 48 samples with 27 abnormal karyotypes. Mapped sites for chromosomes of interest in the sequencing data from the training set were normalized individually by calculating the ratio of the number of sites on the specified chromosome to the number of sites observed on an optimized normalizing chromosome or chromosome set.

Threshold values for trisomy or sex chromosome classification were then established for all chromosomes of interest, and a classification schema was defined.

The algorithm also correctly identified the presence of trisomy 21 in 2 sets of twin pregnancies with at least 1 affected fetus and 1 case of trisomy 9. The authors concluded that MPS is capable of detecting multiple fetal chromosomal abnormalities from maternal plasma when an optimized algorithm is used.

In a study by Palomaki and colleagues and sponsored by the Women and Infants Hospital of Rhode Island in collaboration with Sequenom Center for Molecular Medicine, the performance of maternal cell-free fetal DNA sequencing for the detection of trisomy 18 and 13 was a secondary endpoint.

Of the pregnancies with matched euploid controls, samples were identified with trisomy 21, 62 samples with trisomy 18, and 12 samples with trisomy One trisomy 13 sample was signed out as normal false negative.

Overall, testing failed to provide a clinical interpretation in 17 participants 0. Blood samples were collected in a prospective, blinded study from female participants undergoing prenatal diagnostic procedures at 60 locations in the United States. An independent biostatistician selected all singleton pregnancies with any abnormal karyotype and a balanced number of randomly selected pregnancies with euploid karyotypes.

The gender of fetuses was also determined with of cases No false positives for aneuploidies of chromosomes 13, 18 or 21 were identified, but there was one specimen that was incorrectly identified as monosomy X.

The researchers concluded that this test is highly accurate and can be incorporated into prenatal aneuploidy screening algorithms to reduce the incidence of invasive procedures. Sparks and colleagues b explored the development of a novel prenatal assay based on selective analysis of cell-free DNA in maternal blood for the evaluation of fetal trisomy 21 and trisomy A total of pregnancies, including 39 trisomy 21 and 7 trisomy 18 confirmed fetal aneuploidies, were analyzed using DANSR.

The products from 96 separate subjects were pooled and sequenced together. A standard Z-test of chromosomal proportions was used to distinguish aneuploid samples from low-risk pregnancy samples. DANSR aneuploidy discrimination was evaluated at various sequence depths. At the lowest sequencing depth of , sequencing counts per sample, low-risk cases where distinguished from trisomy 21 and trisomy 18 cases.

Increasing the sequencing depth to , counts per sample substantially improved separation of aneuploid and low-risk cases. A further increase of the sequencing depth to , counts per sample resulted in only marginal improvement. The researchers concluded that DANSR enables highly accurate, cost efficient and scalable non-invasive fetal aneuploidy assessment. Ashoor and colleagues assessed the prenatal detection rate of trisomy 21 and 18 and the false positive rate by chromosome-selective sequencing of maternal plasma cell-free DNA.

In this nested case-control study, cell-free DNA was examined in plasma that was obtained at weeks before chorionic villous sampling from euploid pregnancies, 50 pregnancies with trisomy 21, and 50 pregnancies with trisomy The laboratory personnel were blinded to fetal karyotype. Risk scores for trisomy 21 and 18 were assigned for of the samples that were analyzed. In the 50 cases of trisomy 18, the risk score for trisomy 21 was less than or equal to 0.

In the remaining cases, the risk score for trisomy 21 was less than or equal to 0. The authors also acknowledged that additional research is needed to investigate the accuracy of the test in intermediate-risk and low-risk pregnancies and to expand the spectrum of aneuploidies that could be detected by analysis of maternal plasma cell-free DNA.

The researchers assayed cell-free DNA from a training set and a blinded validation set of pregnant females, consisting of euploidy, 72 trisomy 21, and 16 trisomy 18 pregnancies. FORTE produced an individualized trisomy risk score for each participant and correctly identified all trisomy 21 and trisomy 18 cases from euploid cases. The authors concluded that digital analysis of selected regions in conjunction with FORTE enable accurate, scalable non-invasive fetal aneuploidy detection.

Norton reported on the findings of a multicenter cohort study involving pregnant women with a gestational age at or equal to 10 weeks with singleton pregnancies who were evaluated for the presence of trisomy 21 or trisomy A total of 81 subjects were classified as high-risk for trisomy Thirty-eight subjects were identified as having trisomy 18 present, and 37 were classified as high-risk.

There were two false positive results among the normal cases, for a sensitivity of It was concluded that chromosome-selective sequencing of cell-free DNA and application of an individualized risk algorithm was effective in the detection of fetal trisomy 21 and trisomy Testing for trisomy 21 and trisomy 18 was conducted in 11, women with singleton pregnancies at a gestational age of 12 weeks Dan, A total of subjects were classified as positive, including with trisomy 21 and 47 with trisomy A study by Canick reported on the use of MPS to identify the presence of trisomy 21, trisomy 18, and trisomy 13 in pregnant women with multiple gestations and at high risk of aneuploidy.

Seven twin pregnancies affected by Down syndrome were identified by their karyotypes; two in which both fetuses were affected and five in which just one fetus was affected.

One twin pregnancy discordant for trisomy 13 was also identified. The American College of Medical Genetics and Genomics ACMG has indicated that noninvasive prenatal screening using cell-free DNA should not be used to screen for autosomal aneuploidies other than those involving chromosomes 13, 18, and 21 Gregg, Low-risk pregnancies: Compared with high-risk pregnancies, there is limited evidence evaluating the screening accuracy of cell-free fetal DNA prenatal testing in low-risk pregnancies.

Although some studies suggest the test performance of cell-free fetal DNA aneuploidy screening in a low-risk population is similar to results reported for high-risk pregnancies, these findings are weakened by study design limitations.

The outcome for group 1 was uneventful. In group 2 and 3, 2 anomalies, anorectal malformation and cystic fibrosis, were detected post-natally 6.

The authors concluded that if FEB occurs in isolation, it is a benign condition carrying a favorable prognosis. If multiple additional anomalies or early IUGR are observed, the prognosis tends to be less favorable to extremely poor. Laigaard and colleagues stated that maternal serum A Disintegrin And Metalloprotease 12 ADAM 12 is reduced, on average, in early first trimester Down and Edwards' syndrome pregnancies; however the extent of reduction declines with gestation.

These investigators examined the levels of ADAM 12 at 9 to 12 weeks when the marker might be used concurrently with other established markers. Samples from 16 Down and 2 Edwards' syndrome cases were retrieved from storage and tested together with unaffected singleton pregnancies using a semi-automated time-resolved immuno-fluorometric assay.

Results were expressed in multiples of the gestation-specific median MoM based on regression. The median in Down syndrome was 0. The authors concluded that ADAM12 can not be used concurrently with other markers in the late first trimester. However, it does have the potential to be used earlier in pregnancy either concurrently with other early markers or in a sequential or contingent protocol. The authors stated that more research is needed to reliably predict the performance of either approach.

The concentration of ADAM 12 was determined in gestational week 14 to 19 in 88 DS pregnancies and matched control pregnancies. Medians of normal pregnancies were established by polynomial regression and the distribution of log 10 MoM ADAM 12 values in DS pregnancies and controls determined. Correlations with alpha-fetoprotein AFP and free beta-hCG were established and used to model the performance of maternal serum screening with ADAM 12 in combination with other second-trimester serum markers.

Moreover, they stated that further studies should be conducted to determine whether it may be a useful additional or alternative marker to those currently used in the second-trimester. Serum marker concentrations were measured in monochorionic and dichorionic twin pregnancies and singleton controls to study differences in MoMs.

No statistically significant differences between monochorionic and dichorionic twin pregnancies were found. Correlations between markers in these pregnancies did not differ from singletons. The authors concluded that for first-trimester screening, different parameters for monochorionic and dichorionic twin pregnancies is not necessary.

Furthermore, if ADAM12 and PP13 will be adopted as screening markers, the presented median MoM values, standard deviations and correlation coefficients for twin pregnancies may contribute to a proper twin risk estimation. In a case control study, Torring and colleagues examined if ADAMS is a useful serum marker for fetal trisomy 21 using the mixture model.

Comparison of sensitivity and specificity of first trimester screening for fetal trisomy 21 with or without ADAMS was included in the risk assessment using the mixture model. The concentration of ADAMS increased from week 8 to 11 and was negatively correlated with maternal weight.

The authors concluded that these findings showed moderately decreased levels of ADAMS in cases of fetal aneuploidy in gestational weeks 8 to However, including ADAMS in the routine risk does not improve the performance of first trimester screening for fetal trisomy Cowans et al examined the stability of ADAM with time and at different temperatures. Maternal serum and whole blood pools were stored at 30 degrees C, room temperature and refrigerator temperature or subjected to repeated freeze-thaw cycles.

ADAM levels are not altered following 3 degrees C to room temperature freeze-thaw cycles. The stability of ADAM in whole blood appears similar to that in serum.

The authors concluded that these findings suggested that ADAM may be unstable under many routine laboratory conditions, and the marker's instability may also be partly responsible for the discrepancies in the literature. Koster and colleagues examined if placental protein 13 PP13 could be an additional marker in first trimester screening for aneuploidies.

These researchers assessed differences in multiples of the gestation-specific normal median MoMs , PP13 concentrations were measured in serum samples from DS, trisomy 18 and 13 affected pregnancies and euploid singleton pregnancies 4 for each case matched for duration of storage, maternal weight and age. There was a slight upward trend in MoM values of the DS cases with gestational weeks.

The authors concluded that PP13 does not seem to be a good marker for DS. Li et al compared the difference in maternal serum anti-Mullerian hormone AMH level between DS pregnancies and unaffected pregnancies, and evaluated its performance as a screening marker for DS pregnancy.

A total of pregnancies affected by fetal DS and unaffected controls matched with maternal age and gestational age were selected, and their archived first or second trimester serum retrieved for AMH assay.

There was no significant difference in maternal serum AMH level between pregnancies affected and unaffected by fetal DS. The authors concluded that maternal serum AMH level, as a marker of ovarian age, is not superior to chronological age in predicting DS pregnancies. Iles and colleagues noted that the established methods of antenatal screening for Down syndrome are based on immunoassay for a panel of maternal serum biomarkers together with ultrasound measures.

Recently, genetic analysis of maternal plasma cfDNA has begun to be used but has a number of limitations including excessive turn-around time and cost. These researchers developed an alternative method based on urinalysis that is simple, affordable and accurate.

A total of maternal urine samples 12 to 17 weeks gestation were taken from an archival collection of 2, spot urines collected from women attending a prenatal screening clinic; 18 pregnancies in this set subsequently proved to be Down pregnancies.

Spectral data was normalized and quantitative characteristics of the profile were compared between Down and controls. The ratio of the normalized values at these 2 ranges completely separated the 8 Down syndrome from the 39 controls at 12 to 14 weeks. Discrimination was poorer at 15 to 17 weeks where 3 of the 10 Down syndrome cases had values within the normal range. The authors concluded that direct MALDI ToF mass spectral profiling of maternal urinary has the potential for an affordable, simple, accurate and rapid alternative to current Down syndrome screening protocols.

Trivedi and Iles stated that in DS the precise cellular mechanisms linking genotype to phenotype is not straightforward despite a clear mapping of the genetic cause. The urinary metabolome of maternal urine from women with and without an aneuploid pregnancy predominantly DS were compared by both zwitterionic hydrophilic interaction chromatography ZIC-HILIC and reversed-phase liquid chromatography RPLC coupled to hybrid ion trap time of flight mass spectral analysis.

A metabolomics profiling-based maternal urinary screening test modeled from this separation data would detect approximately 87 and Hu and Zhou noted that DS results in patients suffering from delayed body growth, special facies, mild-to-moderate mental retardation and other symptoms, seriously affecting the life of patients.

These researchers examined the association between Down's syndrome critical region 4 DSCR4 gene methylation in plasma in high-risk pregnant women with DS in early pregnancy referred to as pregnant women in early pregnancy and DS, in order to screen new epigenetic markers for the clinical diagnosis of DS.

DNA in peripheral blood cells and plasma in pregnant women in early pregnancy were treated with hydrosulphit; DSCR4 genes with different methylation levels were amplified by methylation-specific polymerase chain reaction PCR , and the methylation difference of the CpG site of the DSCR4 amplification product in peripheral blood DNA was verified via restriction endonuclease analysis.

Additionally, DSCR4 showed a low methylation status in plasma but a high methylation status in peripheral blood cells. The authors stated that these results suggested that the DSCR4 gene was differentially methylated in peripheral blood DNA in pregnant women in early pregnancy. Furthermore, DSCR4 exists in a non-methylated state in plasma and in a hyper-methylated state in blood cells. They noted that DSCR4 can therefore promote the migration and invasion of trophocytes and serve as an epigenetic marker of non-invasive clinical diagnosis of DS.

The authors concluded that this study provided a theoretical basis for the non-invasive prenatal diagnosis of DS and screened new biomarkers for maternal-fetal epigenetic differences; it also provided a new perspective for studying the role of DSCR4 in pathological process of DS and placental development. In a proof-of-principle, pilot study, Huang and colleagues presented a novel silicon-based nano-structured microfluidics platform named as "Cell Reveal" to demonstrate the feasibility of capturing circulating fetal nucleated red blood cells fnRBC and extra-villous cytotrophoblasts EVT for cell-based non-invasive prenatal diagnosis cbNIPD.

The automated computer analysis software was used to identify the targeted cells through additional immunostaining of the corresponding antigens.

The identified cells were retrieved for whole genome amplification for subsequent investigations by micro-manipulation in 1 microchip, and left in-situ for subsequent fluorescence in-situ hybridization FISH in another microchip. The genetic investigations performed in the verification group confirmed the captured cells to be fetal origin. The authors concluded that this report was one of the first few to verify the capture of fnRBC in addition to EVT; and the scalability of their automated system made them one step closer toward the goal of in-vitro diagnostics.

These researchers developed a class of nano-Velcro microchips to effectively enrich a subcategory of CFNCs, i. These investigators first established a nano-imprinting fabrication process to prepare the LCM-compatible nano-Velcro substrates.

Using maternal blood samples collected from expectant mothers carrying a single fetus, the cTB-derived aCGH data were able to detect fetal genders and chromosomal aberrations, which had been confirmed by standard clinical practice. The authors concluded that these findings supported the use of nano-Velcro microchips for cTB-based non-invasive prenatal genetic testing, which holds potential for further development toward future NIPD solution. PreSeek is a cell-free fetal DNA non-invasive prenatal multi-gene sequencing screen for multiple Mendelian monogenic disorders using maternal blood.

PreSeek does not screen for fetal chromosome, or other copy number, abnormalities commonly detected by traditional aneuploidy NIPT. Positive screening results should always be followed-up with an invasive, diagnostic test before any medical decisions are made.

Currently, there are no published studies or guidelines regarding this test. Carmichael and colleagues determined the performance of a 5-serum marker plus US screening protocol for trisomies 13, 18 and 21 T13, T18 and T Gaussian distributions of multiples of the median values were used to estimate modeled FPR and detection rate DR. The authors concluded that an expanded conventional screening test could achieve very high DRs with low FPRs.

Such screening fitted well with proposed contingency protocols utilizing cell-free DNA as a secondary or reflex but also provided the advantages of identification of pregnancies at risk for other adverse outcomes such as early-onset pre-eclampsia. The authors stated that the drawbacks of the study were that it was retrospective and relied on modeling of Gaussian distributions.

Although such an approach may be subject to bias towards better screening performance, such an approach has been used widely in this field. It is likely that in future studies, refinements to the parameters will give more precise assessments of FPR and DR at individual gestational ages.

Review History. Clients who bill for services should verify the code s with the applicable payor to confirm that their use is appropriate in each case. This location is owned by Northwestern Medicine, and is able to access Epic records.

In the spirit of keeping you well-informed, the physicians utilizing HealthLab's laboratory services may not be agents or employees of Northwestern Memorial HealthCare or any of its affiliate organizations, including HealthLab. The cfDNA from the placenta generally reflects the genetic makeup of the developing baby fetus. Although there are many similarities among various versions of NIPS, laboratories may offer opt-in or opt-out choices for things like the sex chromosomes or microdeletions.

It is important to speak to your healthcare practitioner about which test is being recommended for you. NIPS may screen for:. Non-invasive prenatal screening NIPS may be used to assess the risk of a pregnant woman's developing baby fetus having a chromosome disorder, such as Down syndrome trisomy 21 , Edwards syndrome trisomy 18 , or Patau syndrome trisomy It may also be used to identify sex chromosome abnormalities changes to the number of X or Y chromosomes present.

Some laboratories offer additional testing for conditions caused by small segments of missing information on specific chromosomes, called microdeletion syndromes. You should discuss this and other screening options with your healthcare practitioner to ensure it is the best choice for you.

If you are not certain which prenatal screening or diagnostic test is right for you, it may be a good idea to speak with a genetic counselor. The non-invasive prenatal screening NIPS can be offered during or after the tenth week of pregnancy. Samples collected prior to this time are automatically rejected, so it is important to be certain that the pregnancy is at a minimum of 10 weeks along. A NIPS result that is reported as "negative" or as "low risk" means that it is unlikely the baby has any of the specific chromosome disorders that were screened.

Most NIPS tests evaluate the risk for Down syndrome trisomy 21 , Edwards syndrome trisomy 18 and Patau syndrome trisomy 13 , but depending on how your healthcare practitioner ordered the test, it may also include the sex chromosomes X and Y and certain microdeletion syndromes.

It is important to remember that NIPS is a screening test, not a diagnostic test, so it is possible that the baby actually has a chromosomal disorder, even though the screening results show low risk a false-negative result. In addition, NIPS does not screen every chromosome and does not detect the many genetic disorders that are caused by smaller changes in DNA. This means that other chromosome abnormalities or genetic disorders could be present and would not be identified by NIPS.

It is important to note that, while the test's ability to correctly identify pregnancies at increased risk of Down syndrome is high, it is not as good at correctly identifying abnormalities of other chromosomes, including 18, 13 and X. It is important to remember that NIPS is a screening test and not a diagnostic test, so it is possible that the baby actually does not have the disorder indicated false-positive result.

Diagnostic testing can be performed with either chorionic villus sampling CVS , which samples placental tissue, between the 10th and 13th week of pregnancy, or amniocentesis amnio , which samples amniotic fluid, after about 16 weeks of pregnancy. Chromosomal analysis by karyotyping or chromosomal microarray is performed on the sample to rule out or confirm a suspected chromosome disorder.

There are a number of factors that may affect this measurement, such as the gestational age, the presence of multiple fetuses e. Obese women tend to have a lower concentration of placental cfDNA in their bloodstream. For mothers who are obese, their healthcare practitioner may offer a prenatal screen that is less affected by maternal weight than NIPS. There are different versions of NIPS offered by different laboratories. Healthcare practitioners should be prepared to offer pre- and post-test genetic counseling for the version of NIPS that are chosen for their patients.

National Society of Genetic Counselors. Accessed Jan. Palomaki GE, et al. Prenatal screening for common aneuploidies using cell-free DNA. Gregg AR, et al. Noninvasive prenatal screening for fetal aneuploidy, update: A position statement of the American College of Medical Genetics and Genomics.

Genetics in Medicine. Allyse MA, et al. No compliance statements are in use for this test. Note Additional information related to the test. View Hotline History. Hotline History. Date of Change. CPT codes are provided only as guidance to assist clients with billing. CPT coding is the sole responsibility of the billing party. Learn more. Amniocentesis is a prenatal diagnostic test that can detect significant chromosome problems.

Find frequently asked questions regarding Amniocentesis here. Screening is offered for eleven genetic disorders which are more common in individuals of Ashkenazi Jewish descent. Learn more and book an appointment here. Cystic fibrosis CF is one of the most common life threatening genetic diseases, affecting approximately 1 out of 3, people. Find more info and FAQs here.

For pregnant women, to assess the risk of your developing baby fetus having certain chromosome disorders. Cpt code for cell free dna test or after the 10 th week of pregnancy. You may be able to find your test results on your laboratory's website or patient portal. However, you are i need an antivirus software for free at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test s you had performed. Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The cpt code for cell free dna test ranges for your tests can be found on your cpt code for cell free dna test report. They are typically xode to the right of your results. If you do not have cekl lab report, consult tsst healthcare provider or the laboratory that performed the test s to obtain the cpt code for cell free dna test range. Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to cide ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases. While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, cpt code for cell free dna test reagents, and techniques. This is a reason why gest few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory cpy performed your test to evaluate whether your results cpt code for cell free dna test "within normal limits. Non-invasive prenatal screening NIPS helps determine the risk that a pregnant woman's developing baby fetus has a chromosome disorder. It is cpt code for cell free dna test a diagnostic foor, meaning tesh cannot tell for certain whether your baby is affected or unaffected. If NIPS shows an increased risk for a specific chromosome disorder, diagnostic testing by chorionic villus sampling CVS or amniocentesis is recommended to establish the true diagnosis. The cfDNA from the placenta generally reflects the genetic makeup of the developing baby fetus. Although there are many similarities among various versions of NIPS, laboratories may offer opt-in or opt-out choices for things like the sex chromosomes or microdeletions. cpt code for cell free dna test What is being tested? Cell-free fetal DNA (cffDNA) is genetic material that is released by the placenta and circulates in a woman's blood during pregnancy. Testing (NIPT)/Cell Free DNA Testing. The labs listed below Diagnosis codes (​ICD) that may be used: O (first pregnancy CPT Code: 2. You must order test code NIPS and send the completed paperwork in with the sample. The receipt Letter of Medical Necessity for Cell-Free DNA Prenatal Screen Genetic Testing and CLIA-certified laboratory, using CPT code: Cell-free fetal DNA testing for indications other than those listed in The following CPT/HCPCS codes listed below may be used for this testing. Non-invasive prenatal screening tests, also known as cell-free DNA NOTE: CPT code (Molecular cytogenetic testing, DNA probe. Whole blood in Cell-Free DNA BCT Tube. All specimens must be collected using the NIPT ANEU kit (ARUP Supply #) available online through eSupply. The test measures the small fragments of fetal DNA in the mother's blood, and can. CFTR gene variants (CPT code ) as described by the American The sensitivity and specificity of cell-free DNA screening has been. (carrier screening) and testing of fetal or embryonic DNA (prenatal diagnosis, Prenatal cell-free DNA screening (cfDNA) (CPT codes or. Trisomy It can also be used to screen for fetal rhesus (Rh) blood type and fetal sex. Some prenatal cell-free DNA screening tests. The authors concluded that while non-invasive prenatal testing is a screening method and confirmatory results must be obtained by ultrasound or genetic diagnosis, the sex-score determination presented herein offers an accurate and useful approach to characterizing fetus sex in twin pregnancies in a non-invasive manner early on in pregnancy. The pooled specificity was Although such an approach may be subject to bias towards better screening performance, such an approach has been used widely in this field. Already have an account? Noninvasive prenatal testing for fetal aneuploidy: Clinical assessment and a plea for restraint. UpToDate [online serial]. Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population - a systematic review and meta-analysis. Ross H, Elias S. Discrimination was poorer at 15 to 17 weeks where 3 of the 10 Down syndrome cases had values within the normal range. A total of maternal urine samples 12 to 17 weeks gestation were taken from an archival collection of 2, spot urines collected from women attending a prenatal screening clinic; 18 pregnancies in this set subsequently proved to be Down pregnancies. cpt code for cell free dna test